| SVA | selective vagotomy and antrectomy; selective visceral angiography; sequential ventriculoatrial [paci... |
|---|---|
| TRP | Tubular Reabsorption of Phosphate |
| APR | abdominoperineal resection; absolute proximal reabsorption; acute phase reaction or reactant; amebic... |
| FTR | fractional tubular reabsorption |
| TMg | maximum tubular reabsorption rate for glucose |
| selective medium | <cell culture> A medium which allows the growth of certain types of microorganisms in preference to others. For example: an antibiotic-containing medium allows the growth of only those microorganisms which are resistant to this antibiotic. (09 Oct 1997) |
|---|---|
| selective memory | <psychology> Reception or retrieval of only some of the events in an experience. (05 Mar 2000) |
| selective oestrogen-receptor modulator | <pharmacology> An antioestrogen which possesses some, but not all, of the actions of oestrogen. For example, raloxifene (evista) is classified as a SERM because it prevents bone loss (like oestrogen) and lowers serum cholesterol (like oestrogen) but (unlike oestrogen) does not stimulate the endometrial lining of the uterus. Acronym: SERM (17 Jul 2002) |
| selective reduction | <obstetrics> A technique for intrauterine termination of one or more foetuses while leaving one or more foetuses undisturbed, usually in pregnancies with foetal anomalies or with multiple gestations. (05 Mar 2000) |
| selective stain | <technique> A stain that colours one portion of a tissue or cell exclusively or more deeply than the remaining portions. (05 Mar 2000) |
| ion selective electrode | An electrode half cell, with a semi permeable membrane that is permeable only to a single ion. The electrical potential measured between this and a reference half cell (e.g. A calomel electrode) is thus the Nernst potential for the ion. Given that the solution filling the ion selective electrode is known, the activity (rather than concentration) of the ion in the unknown solution can be measured. Commercial ion selective electrodes frequently use a hydrophobic membrane containing an ionophore, such as valinomycin (for potassium) or monensin (for sodium). A pH electrode is made with a thin membrane of pH sensitive (i.e. Proton permeable) glass. (18 Nov 1997) |
| ion-selective electrodes | Electrodes which can be used to measure the concentration of particular ions in cells, tissues, or solutions. (12 Dec 1998) |
| a1-trypsin inhibitor | A glycoprotein that is the major protease inhibitor of human serum, is synthesised in the liver, and is genetically polymorphic due to the presence of over 20 alleles; individuals appropriately homozygous are deficient in a1-trypsin and are predisposed to pulmonary emphysema and juvenile hepatic cirrhosis because of alterations in the amino acid and sialic acid components of the glycoprotein. A1-Antitrypsin also inhibits thrombin. Synonym: a1-trypsin inhibitor, human a1-proteinase inhibitor. (05 Mar 2000) |
| ACE inhibitor | <pharmacology> A group of antihypertensive medications that work by inhibiting an enzyme (angiotensin-converting enzyme) that is important in the regulation of blood pressure. Studies have also indicated that it may help prevent or slow the progression of kidney disease in patients with diabetes. Examples include: captopril, ramipril, enalapril, losartan potassium, bepridil and lisinopril. (12 Mar 1998) |
| aldose reductase inhibitor | <pharmacology> A class of drugs being studied as a way to prevent eye and nerve damage in people with diabetes. Aldose reductase is an enzyme that is normally present in the eye and in many other parts of the body. It helps change glucose (sugar) into a sugar alcohol called sorbitol. Too much sorbitol trapped in eye and nerve cells can damage these cells, leading to retinopathy and neuropathy. Drugs that prevent or slow (inhibit) the action of aldose reductase are being studied as a way to prevent or delay these complications of diabetes. (09 Oct 1997) |
| angiotensin-converting enzyme inhibitor | <pharmacology> A class of drugs used in the treatment of hypertension and heart failure. They exert their haemodynamic effect mainly by inhibiting the renin-angiotensin system and produce a reduction of peripheral arterial resistance. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (14 Aug 2000) |
| aromatase inhibitor | Drugs, such as aminoglutethimide, that inhibit aromatase, an enzyme used in the synthesis of oestrogens. (05 Mar 2000) |
| beta-lactamase inhibitor | <pharmacology> Drugs such as clavulanic acid, which are used to inhibit bacterial beta-lactamases; often used with a penicillin or cephalosporin to overcome drug resistance. (05 Mar 2000) |
| Bowman-Birk inhibitor | A polypeptide that will inhibit both trypsin and chymotrypsin. (05 Mar 2000) |
| C1 esterase inhibitor | An a2-neuraminoglycoprotein that inhibits the enzymatic activity of C1 esterase, the activated first component of complement. A deficiency of this inhibitor results in a lack of inhibition of C1r and C1s leading to uncontrolled activation of the complement cascade and oedema. (05 Mar 2000) |